Imunexus is not a typical biotechnology company...
The imunexin™ platform rapidly generates bispecific or trispecific therapeutics by converting existing monospecific drugs into multispecific medicines.
The platform introduces additional therapeutic functions while preserving the original drug mechanism of action. This strategy may reduce development risk, cost and timelines.
By adding new therapeutic properties to existing drugs, Imunexus generates novel intellectual property and new patentable inventions. The company currently holds multiple patent families, including granted patents and applications under examination.
By enhancing existing biologics rather than creating entirely new drugs, development timelines and costs may be reduced.
Imunexus currently has several programs in development:
The technology has also been externally validated through collaborations with The Baker Heart and Diabetes Institute and Mesoblast Ltd.
Pharmaceutical companies are actively seeking multispecific technologies, with most partnerships occurring during the discovery or preclinical stages of development.
